BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37775115)

  • 21. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
    Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
    J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
    Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
    Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
    Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
    Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
    Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RBM-MHC: A Semi-Supervised Machine-Learning Method for Sample-Specific Prediction of Antigen Presentation by HLA-I Alleles.
    Bravi B; Tubiana J; Cocco S; Monasson R; Mora T; Walczak AM
    Cell Syst; 2021 Feb; 12(2):195-202.e9. PubMed ID: 33338400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex.
    Dao T; Mun SS; Molvi Z; Korontsvit T; Klatt MG; Khan AG; Nyakatura EK; Pohl MA; White TE; Balderes PJ; Lorenz IC; O'Reilly RJ; Scheinberg DA
    JCI Insight; 2022 Mar; 7(5):. PubMed ID: 35260532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
    Warren EH; Greenberg PD; Riddell SR
    Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
    Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
    Front Immunol; 2018; 9():912. PubMed ID: 29780384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.
    Cobbold M; De La Peña H; Norris A; Polefrone JM; Qian J; English AM; Cummings KL; Penny S; Turner JE; Cottine J; Abelin JG; Malaker SA; Zarling AL; Huang HW; Goodyear O; Freeman SD; Shabanowitz J; Pratt G; Craddock C; Williams ME; Hunt DF; Engelhard VH
    Sci Transl Med; 2013 Sep; 5(203):203ra125. PubMed ID: 24048523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.
    Mohammed F; Stones DH; Zarling AL; Willcox CR; Shabanowitz J; Cummings KL; Hunt DF; Cobbold M; Engelhard VH; Willcox BE
    Oncotarget; 2017 Aug; 8(33):54160-54172. PubMed ID: 28903331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403.
    Terakura S; Murata M; Warren EH; Sette A; Sidney J; Naoe T; Riddell SR
    Transplantation; 2007 May; 83(9):1242-8. PubMed ID: 17496542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.
    Hasan AN; Kollen WJ; Trivedi D; Selvakumar A; Dupont B; Sadelain M; O'Reilly RJ
    J Immunol; 2009 Aug; 183(4):2837-50. PubMed ID: 19635907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors.
    Georgopoulos AP; James LM; Charonis SA; Sanders M
    Cancer Inform; 2023; 22():11769351231172604. PubMed ID: 37251656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.